Screener / SEC EDGAR /CIK 0001158895 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

Lemaitre Vascular Inc LMAT

Compare with peers Embed
The 10-K against last year's

166 changes: 54 added, 18 removed, 91 reworded, 3 quiet changes

10-K Feb 26, 2026 vs Feb 28, 2025

10-K 0001193125-26-073360 (Feb 26, 2026) vs 10-K 0001437749-25-005637 (Feb 28, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

187 paragraphs · 37 new · 86 reworded · 5 gone · 10-K Feb 26, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 75 · 48% changed Every version of it
We rely upon a combination of information technology systems and traditional recordkeeping to operate our business. In the ordinary course of business, we collect, store, and transmit business-critical and confidential information (including, but not limited to, information about our business, financial information, personal data, intellectual property, and in some very limited instances, patient data). Our information technology and information security systems and records are potentially vulnerable to security breaches, service interruptions, data loss, or malicious attacks resulting from inadvertent or intentional actions by our employees, vendors, or other third parties. In addition, due to our international presence and mobile sales force, we have implemented remote work arrangements for certain employees, and those employees may use outside technology and systems that are vulnerable to security breaches, service interruptions, data loss, or malicious attacks, including by third parties.
Paragraph 117 · 41% changed Every version of it
Each medical device that we wish to market in the United States generally must receive either 510(k) clearance or PMA approval. Either process can be lengthy and expensive. The FDA’s 510(k) clearance procedure usually takes three to twelve months. Although 510(k) clearances have been obtained for nearly all of our current products that require such clearances, the FDA may condition, limit or prohibit our sales of these products if safety or effectiveness problems develop with the devices. Our new products or significantly modified existing products could be denied 510(k) clearance.
Paragraph 15 · 38% changed Every version of it
The •The use or misuse of our products and the or tissues we distribute may result in injuries that lead to product liability lawsuits claims, recalls or legal actions, which regulatory actions that could be costly to costly, damage our reputation and adversely affect our business.
Paragraph 186 · 36% changed Every version of it
We In February 2011, our Board of Directors adopted a quarterly dividend program for the purpose of returning capital to our stockholders. However, we have not established a minimum dividend payment level for our common stockholders and there are no assurances of our ability to pay dividends to common stockholders in the future.
Paragraph 69 · 35% changed Every version of it
We rely on sole- and limited-source suppliers for many of our important components and certain products, including our XenoSure biologic patch, VascuCel and CardioCel biologic patch, Artegraft biologic graft, vascular graft and Omniflow biosynthetic vascular graft, and RestoreFlow allografts. graft. There are relatively few, or in some cases no, alternative, validated sources of supply for our sole-sourced materials and products. We do not always have supply agreements in place with suppliers, instead placing orders on an as-needed basis. At any time, these suppliers could discontinue or become incapable of the manufacture or supply of these materials or products. We do not ordinarily carry a significant inventory of these materials and products. Identifying and qualifying additional or replacement suppliers, if required, may not be accomplished quickly or at all and could involve significant additional costs. Any supply interruption from our suppliers or failure to obtain replacement suppliers would interrupt our ability to manufacture our products and result in production delays and increased costs. This could lead to loss of sales and customers, and our results of operations could be harmed. In some cases, changes to raw material suppliers or use of alternative raw materials may require significant testing and subsequent regulatory approval.
Paragraph 167 · 33% changed Every version of it
require •require us to enter into royalty or licensing agreements in order to obtain the right to use a third party’s intellectual property, which agreements may not be available on terms acceptable to us or at all; divert the attention of our management and key personnel from other tasks important to the success of our business; or result in our customers or potential customers deferring or limiting their purchase or use of the affected products until resolution of the litigation.
Paragraph 178 · 27% changed Every version of it
adverse •adverse regulatory actions which may actions, including those that involve fines, those that necessitate recalls of our products or services services, or warning letters that negatively affect the markets for our products or services;
Paragraph 136 · 26% changed Every version of it
In the event that any of our products prove to be defective, we can voluntarily recall, or the FDA or foreign equivalent could require us to recall, any of our products. In the EU and UK, adverse event reporting requirements mandate that we report incidents which led or could have led to death or serious deterioration in health. Recalls, whether voluntary or required, could result in significant costs to us and significant adverse publicity. In severe instances, the FDA may also issue a warning letter and/or letter, destruction of defective product product, and/or order the suspension or cessation of manufacturing of defective product. Additionally, if someone is harmed by a malfunction or a product defect, we may experience product liability claims for such defects. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital and may harm our financial results. Future recalls or claims could also result in significant costs to us and significant adverse publicity, which could harm our ability to market our products in the future. For example, in April 2025, we voluntarily notified our regulatory bodies of an inadequate seal on the packaging of our TufTex Over-the-Wire, Pruitt Occlusion, and Pruitt Irrigation catheters, which may result in a compromised sterile barrier. Notice was provided to each of our customers of the inadequate seal, and customers were offered a product replacement for any existing inventory on hand. The financial impact of the voluntary notification is not expected to be material to our business. Additionally, in August 2025, the FDA issued us a warning letter detailing findings from an April 2025 inspection at our Artegraft facility in North Brunswick. We have responded to all the cited observations, and the FDA has indicated that they will confirm implementation in a follow-up inspection. The financial impact of this warning letter is not expected to be material to our business, and there has been no disruption to our Artegraft sales.

MD&A

107 paragraphs · 17 new · 66 reworded · 13 gone · 10-K Feb 26, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 45 · 39% changed
Other income (expense). Other income (expense) primarily includes interest income and expense, dividend income, realized gains (losses) from the sale of debt and equity investments, unrealized gains (losses) from equity investments, interest expense for the convertible senior notes, foreign currency gains (losses), and other miscellaneous gains (losses).
Paragraph 25 · 37% changed
During 2024, •During 2025, we made the decision to wind down the PeriVu Angioscope CardioCel 3D and DuraSure product line. lines. These product lines totaled approximately $0.5 million in 2025 revenues. Additionally, in 2025 we made the decision to wind down the AnastoClip AC Closure System in North America. This product totaled approximately $0.9 $0.7 million in 2024 2025 revenues.
Paragraph 59 · 33% changed
General Research and administrative. development. For the year ended December 31, 2023, general 2025, research and administrative development expenses increased 11% decreased 10% to $31.8 $14.1 million. The increase decrease was primarily driven primarily by higher compensation and related expenses of $1.7 million due to an increase lower third party service fees, which resulted in personnel. Additionally, decreased professional fees and outside services expenses related to MDR activities of $1.8 million, partially offset by increased $1.4 facilities expenses of $0.3 million and compensation and related expenses of $0.1 million. The increase in compensation and related expenses was partially offset by the ERC received in 2025, which had a favorable impact reducing research and development expenses by $0.3 million. As a percentage of net sales, general research and administrative development expenses decreased to 16% 6% for the year ended December 31, 2023, 2025, down from 18% in 7% for the prior period. year ended December 31, 2024.
Paragraph 58 · 32% changed
General and administrative. For the year ended December 31, 2024, 2025, general and administrative expenses increased 14% 16% to $36.3 $42.0 million. The increase was driven primarily by higher headcount and related recruiting fees, accrued bonus, and stock compensation expenses, wage increases, which resulted in increased compensation and related expenses of $2.1 million. $4.1 million, which was partially offset by the ERC. Additionally, professional fees and outside services expenses increased $1.2 million and facilities expenses increased $0.8 $1.0 million and travel and training expenses increased $0.2 million. The ERC received in 2025 had a favorable impact, reducing general and administrative expenses by $0.3 million, offset by third party consultant fees of $0.7 million. As a percentage of net sales, general and administrative expenses remained consistent at increased to 17% for the year ended December 31, 2025, up from 16% for the year ended December 31, 2024 versus the prior period. 2025.
Paragraph 55 · 31% changed
Gross profit increased $23.9 $27.6 million, or 19%, 18%, to $178.5 million for the year ended December 31, 2025, as compared to $150.9 million for the year ended December 31, 2024, and gross margin increased by 290 basis points to 68.6% 71.5% in the period. period, as compared to 68.6% for the year ended December 31, 2024. The increase in gross profit was driven primarily by increased sales, particularly from allograft preservation services, bovine vascular patches, carotid shunts grafts, valvulotomes, and bovine grafts. shunts, and the receipt of the U.S. Employee Retention Credit ("ERC"). The increase in gross margin was driven primarily by the ERC, greater manufacturing efficiencies efficiencies, and sales price increases, which was partially offset by increased shipping and warehousing costs and unfavorable product mix, including increased sales of comparatively lower margin allograft preservation services, ovine grafts, and increased excess and obsolescence charges. single lumen embolectomy catheters. The ERC received in 2025 had a favorable impact of $2.7 million, or 109 basis points, to the gross margin.
Paragraph 21 · 29% changed
In June 2020, •In December 2025, we entered into an agreement with Artegraft Andramed GmbH to purchase the assets of their bovine graft AndraValvulotome business for $72.5 $1.8 million plus additional payments of up to $17.5 $0.8 million, contingent upon unit sales. the passage of time and, separately, receipt of CE mark approval.
Paragraph 57 · 29% changed
Sales and marketing. For the year ended December 31, 2024, 2025, sales and marketing expenses increased 14% 17% to $46.7 $54.5 million. The increase was driven primarily by higher sales representative headcount, headcount and wage increases, which resulted in increased compensation and related expenses of $4.2 million. $6.6 million, which was partially offset by the ERC. Additionally, travel, training, professional fees and sales meeting outside services expenses increased $1.7 $1.1 million in 2024. and travel and training expenses increased $0.6 million. Sales rep force headcount was 152 160 as of December 31, 2024, 2025, a 12% 5% increase from December 31, 2023. 2024. The ERC received in 2025 had a favorable impact, reducing sales and marketing expenses by $0.8 million. As a percentage of net sales, sales and marketing expenses remained consistent at increased to 22% for the year ended December 31, 2025, up from 21% for the year ended December 31, 2024 versus the prior period. 2024.
Paragraph 40 · 28% changed
Cost of sales. We manufacture the majority of the products that we sell. Our cost Cost of sales consists primarily of manufacturing personnel, personnel wages, raw materials and components, depreciation of property and equipment, and other allocated manufacturing overhead, as well as including an allocation of our quality department expenses. Additionally, cost of sales includes the freight expense expenses we pay to ship products to customers. customers, inventory scrap charges, and excess and obsolescence expenses.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Accounting Policies496 words changed in this paragraph; it is 37% similar to last year's version.
Below is a disaggregation of the Company’s revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands): Year ended December 31, 2025 2024 2023 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Americas $ 159,665 $ 144,583 $ 130,308 Europe, Middle East and Africa 73,122 59,969 51,099 Asia Pacific 16,815 15,311 12,077 Total $ 249,602 $ 219,863 $ 193,484 The Company does not carry any contract assets or contract liabilities, as there are generally no unbilled amounts due from customers under contracts for which the Company has partially satisfied performance obligations, or amounts received from customers for which the Company has not satisfied performance obligations. The Company satisfies its performance obligations under revenue contracts within a short time period from receipt of the orders, and payments from customers are typically received within 30 to 60 days of fulfillment of the orders, except in certain geographies such as Italy, Spain, and France, where the payment cycle is customarily longer, but less than 12 months. Accordingly, there is no significant financing component to the Company’s revenue contracts. Additionally, the Company has elected as a policy that incremental costs (such as commissions) incurred to obtain contracts are expensed as incurred, due to the short-term nature of the contracts. Customers returning products may be entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least 18 months remaining prior to its expiration date, or 12 months for the Company’s hospital customers in Europe, and generally be returned within 30 days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to the Company, either for exchange or credit, has not been material. Nevertheless, the Company provides for an allowance for future sales returns based on the percentage of 12 months historical returns applied against the Company’s recognized period sales, which requires judgment. The Company’s cost of replacing defective products has not been material and is accounted for at the time of replacement. Sales Returns and Allowances The Company maintains a provision for potential returns of defective or damaged products, and invoice adjustments. The Company adjusts the provision using the expected value method based on historical experiences. Increases to the provision reduce revenue and accounts receivable. Accounts Receivable and Allowance for Credit Losses The Company’s accounts receivable are with customers based in the United States and internationally. Accounts receivable generally are due within 30 to 60 days of invoice and are stated at amounts due from customers, net of an allowance for credit losses and sales returns, other than in certain European markets where the payment cycle is customarily longer. Opening balance accounts receivable at January 1, 2024 was $25.1 million. The Company performs ongoing credit evaluations of the financial condition of its customers and adjusts credit limits based upon payment history and the current creditworthiness of the customers, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections, and payments from customers, and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues the Company identifies. The Company closely monitors outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the United States and international economies. The Company’s European sales to government-owned or supported customers such as hospitals, distributors and agents, particularly in Italy, Spain, and France, may be subject to significant payment delays due to government austerity measures impacting funding and payment practices. As of December 31, 2025, the Company’s receivables in Italy, Spain, and France totaled $1.5 million, $1.2 million and $1.7 million, respectively. Receivables balances with certain government-owned hospitals and government-supported customers in these countries can

Source: 10-K text, Note 1 – Description of Business and Summary of Significant Accounting Policies, 10-K 0001193125-26-073360 vs 10-K text, Note 1 – Significant Accounting Policies and Related Matters, 10-K 0001437749-25-005637

Legal Proceedings304 words changed in this paragraph; it is 48% similar to last year's version.
8. Commitments Leases The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, manufacturing and distribution, as well as automobiles and printing equipment. As of December 31, 2025, the Company had the following building and facility leases capitalized on the balance sheet: Location (leases) Purpose Approx. Sq. Ft. Expiration ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── ──────────────────────────────────────────────────────────────────────────────────────────────────────── Americas Burlington, MA (4) Corporate headquarters and manufacturing 96,476 December 2034 North Brunswick, NJ Artegraft biologic business 16,732 October 2029 Fox River Grove, IL (2) RestoreFlow allografts business December 2026 Burlington, MA US distribution 12,878 December 2030 Fox River Grove, IL RestoreFlow allografts business 9,754 December 2026 Fox River Grove, IL RestoreFlow allografts business 4,878 November 2025 Vaughn, Vaughan, Canada Canada sales office and distribution 3,192 February 2026 Europe, Middle East and Africa Sulzbach, Germany European headquarters and distribution 21,410 June 2031 Milan, Italy Italy sales office and distribution 5,705 September 2027 Hereford, England United Kingdom sales office and distribution 3,575 October 2029 Maisons-Alfort, France France sales office 3,492 February 2030 Zurich, Glattbrugg, Switzerland Switzerland sales office and distribution 2,935 February 2030 Dublin, Ireland Ireland sales office and distribution September 2030 Madrid, Spain Spain sales office 2,260 and distribution June 2029 Asia Pacific Tokyo, Japan Japan sales office and distribution 4,236 July 2025 2027 Shanghai, China China sales office and distribution 3,432 October 2027 Docklands, Australia Australia sales office and distribution April 2030 Bangkok, Thailand Thailand sales office and distribution 2,810 August 2026 Kensington, Australia Australia sales office and distribution 2,551 June 2025 Seoul, Korea Korea sales office and distribution 2,300 April 2027 Singapore Asia Pacific headquarters and distribution 1,270 June 2026 Shanghai, China China sales office and distribution 1,152 August 2025 Ballarat, Australia Supply facility Up to 350 acres December 2030 Operating lease right-of-use ("ROU") assets and operating lease liabilities are recognized based on the present value of the future lease minimum payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. None of the Company’s noncancelable lease payments include non-lease components such as maintenance contracts. The Company generally reimburses the landlord for direct operating costs associated with the leased space. The Company has no subleases, and there are no residual value guarantees associated with, or restrictive covenants imposed by, any of its leases. The Company held no assets under finance leases as of December 31, 2025. The Company elected the package of practical expedients

Source: Item 3, via Note 8 – Commitments, 10-K 0001193125-26-073360 vs Item 3, via Note 8 – Commitments and Contingencies, 10-K 0001437749-25-005637

Risk Factors155 words changed in this paragraph; it is 70% similar to last year's version.
In the event that any of our products prove to be defective, we can voluntarily recall, or the FDA or foreign equivalent could require us to recall, any of our products. In the EU and UK, adverse event reporting requirements mandate that we report incidents which led or could have led to death or serious deterioration in health. Recalls, whether voluntary or required, could result in significant costs to us and significant adverse publicity. In severe instances, the FDA may also issue a warning letter and/or letter, destruction of defective product product, and/or order the suspension or cessation of manufacturing of defective product. Additionally, if someone is harmed by a malfunction or a product defect, we may experience product liability claims for such defects. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital and may harm our financial results. Future recalls or claims could also result in significant costs to us and significant adverse publicity, which could harm our ability to market our products in the future. For example, in April 2025, we voluntarily notified our regulatory bodies of an inadequate seal on the packaging of our TufTex Over-the-Wire, Pruitt Occlusion, and Pruitt Irrigation catheters, which may result in a compromised sterile barrier. Notice was provided to each of our customers of the inadequate seal, and customers were offered a product replacement for any existing inventory on hand. The financial impact of the voluntary notification is not expected to be material to our business. Additionally, in August 2025, the FDA issued us a warning letter detailing findings from an April 2025 inspection at our Artegraft facility in North Brunswick. We have responded to all the cited observations, and the FDA has indicated that they will confirm implementation in a follow-up inspection. The financial impact of this warning letter is not expected to be material to our business, and there has been no disruption to our Artegraft sales.

Source: Item 1A, 10-K 0001193125-26-073360 vs Item 1A, 10-K 0001437749-25-005637

MD&A147 words changed in this paragraph; it is 64% similar to last year's version.
The Convertible Notes will mature on February 1, 2030, unless earlier repurchased, redeemed or converted. The proceeds from the issuance of the Convertible Notes were approximately $167.7 million, net of debt issuance costs totaling $4.8 million. The Convertible Notes bear interest at a rate of 2.50% per year year, and interest is payable semiannually in arrears on August 1 and February 1 of each year. For the year ended December 31, 2025, we paid $2.7 million in interest payments. We did not make interest payments for the year ended December 31, 2024. The initial conversion rate is was 8.3521 shares of common stock per $1,000 principal amount of the Convertible Notes, which represents represented an initial conversion price of approximately $119.73 per share of common stock and a premium of approximately 30% over the closing price of our common stock on December 16, 2024. In connection with the most recent payment made on December 4, 2025 of a quarterly cash dividend of $0.20 per share (an increase from the quarterly dividend amount of $0.16 per share as of the time of issuance of the Convertible Notes), the conversion rate of the Convertible Notes was increased to 8.3676 shares of common stock per $1,000 principal amount of the Convertible Notes, which represents a conversion price of approximately $119.51 per share of common stock. A similar adjustment to the conversion rate will be made upon payment of the quarterly cash dividend of $0.25 on March 26, 2026, and upon payment of subsequent quarterly dividends in excess of $0.16 per share. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events as described in the Indenture.

Source: Item 7, 10-K 0001193125-26-073360 vs Item 7, 10-K 0001437749-25-005637

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of LMAT's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 28, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Our business, financial condition, results of operations, cash flows and the trading price of our common stock are subject to numerous risks and uncertainties, including, but not limited to, the following:
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•We may not be able to maintain our historical profit growth rates, which have been driven by pricing increases, sales force expansion and operating leverage, and our operating income results may vary significantly from period to period.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Our ability to grow sales and maintain profitability depends in part on our ability to increase prices or avoid price concessions; competitive pressures, reimbursement changes, healthcare cost containment efforts, and customer purchasing behavior could limit pricing flexibility.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•We operate in highly competitive medical device markets and face competition from companies with greater resources, broader product portfolios, more extensive distribution networks and alternative technologies, including endovascular procedures.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•A significant portion of our growth has historically depended on acquisitions, and our inability to identify, complete or successfully integrate acquisitions or develop new products could adversely affect our growth strategy and operating results.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Adverse global economic conditions, trade tensions, tariffs and currency fluctuations could reduce demand for our products, increase costs and negatively affect our international operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•We derive a substantial portion of our sales from outside the United States and are subject to risks associated with international operations, including regulatory complexity, reimbursement changes, distributor relationships, foreign exchange volatility, political instability and compliance with anti-corruption and trade laws.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Our reliance on sole-source and limited-source suppliers, including suppliers of biologic and tissue-based products, exposes us to supply disruptions that could delay production and processing, increase costs or result in lost sales.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 60
AddedRisk Factors
•Some of our products are sold to clinical call points outside our core vascular surgeon customer base, and our sales representatives may not be successful in expanding adoption in those markets.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Cybersecurity incidents, data breaches, failures of information technology systems, and reliance on third-party service providers could disrupt operations, compromise sensitive information, expose us to regulatory actions or litigation, and harm our reputation.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•The ongoing implementation and expansion of our enterprise resource planning system presents operational and internal control risks that could disrupt business processes and financial reporting.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Our tissue processing, preservation and cryopreservation services are subject to unique operational, sourcing and regulatory risks, including donor tissue availability, accreditation requirements and compliance with complex human tissue laws.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
While we have invested, and continue to invest, in our information technology and information security systems and employee information security training, there can be no assurance that our efforts will prevent all security breaches, phishing/fraud attempts, service interruptions, or data losses. Although we are not aware of having experienced any prior material data breaches, regulatory non-compliance incidents, or cyber security incidents, we may in the future be impacted by such an event, exposing our clients and us to a risk of someone obtaining access to our information, to information of our clients or their customers, or to our intellectual property; disabling or degrading service; or sabotaging systems or information. Any such security breach could result in a loss of confidence in the security of our services; damage our reputation; disrupt our business; require us to incur significant costs of investigation, remediation and/or payment of a ransom; lead to legal liability; negatively impact our future sales; and result in a substantial financial loss.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Joseph P. Pellegrino, Jr. has served as our Chief Financial Officer since 2007 and a member of our Board of Directors since 2016. In August 2024, Mr. Pellegrino announced that he will retire as Chief Financial Officer as of March 7, 2025. He will remain a member of the Board of Directors. Mr. Pellegrino will be replaced by Dorian LeBlanc.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
The price of our common stock experienced significant gains in 2024, reaching an all-time high in November 2024 of $108.09, nearly double where the stock began at the beginning of the year. Our market capitalization currently exceeds $2 billion. A meaningful portion of compensation provided to our more senior employees is provided in the form of equity awards that consist of restricted stock units, or RSUs, performance-based restricted stock units, or PSUs, and stock options. These rewards are partially intended to encourage retention. Historically we have enjoyed high levels of employee retention, particularly at senior levels. If we are unable to grow the price of our common stock, the retention value of employee equity awards could be diminished and our employee retention could suffer.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedRisk Factors
Each The majority of our executive team, including our Chief Executive Officer, Chief Financial Officer, our President, and our Senior Vice President, Operations have President of Operations, has significant tenure with the company; are is highly knowledgeable of the Company’s business, operations, budgeting, strategy, product offerings, resources, and personnel; maintain and maintains key external relationships on behalf of the Company; and have been integral to the success of the Company.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The As of December 31, 2025, the conversion rate is 8.3521 8.3676 shares of common stock per each $1,000 principal amount of Notes, or approximately $119.73 $119.51 per share, a 30% premium over the closing price on the date of pricing of the Convertible Notes. share.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Although 510(k) clearances have been obtained for nearly all of our current products that require such clearances, the FDA may condition, limit or prohibit our sales of these products if safety or effectiveness problems develop with the devices.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We have such licenses or registrations, and we believe we are in compliance with applicable state laws and regulations relating to clinical laboratories and tissue banks that store, preserve, and distribute donated human tissue designed to be used for medical purposes in human beings.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Although we offer training for physicians, physicians in accordance with our products' instructions for use, we do not require that physicians be trained in the use of our products, and physicians may use our products incorrectly or in procedures not contemplated by us. us or our products' instructions for use.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We However, we have not established a minimum dividend payment level for our common stockholders and there are no assurances of our ability to pay dividends to common stockholders in the future.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We rely on sole- and limited-source suppliers for many of our important components and certain products, including our XenoSure biologic patch, VascuCel and CardioCel biologic patch, Artegraft biologic graft, vascular graft and Omniflow biosynthetic vascular graft, and RestoreFlow allografts. graft.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
While we have largely completed the implementation of a new enterprise resource planning, or ERP, system in the United States, States and United Kingdom, we are continuing to work on expand its adoption internationally.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
If those regulatory bodies feel believe that we have failed to comply with regulatory standards, there can be no assurance that any approval, licensure, or registration will not be subsequently withdrawn, suspended or conditioned upon extensive post-market study requirements, even after having received marketing approval or clearance or licenses and registrations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Our discussion and analysis of our financial condition and results of operations for 2025 as compared to 2024 are discussed below. For a discussion of our financial condition and results of operations for 2024 as compared to 2023, please refer to Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2024 Annual Report on Form 10-K, except as set forth below.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Separately, our regulatory efforts to maintain approvals in the EU and the United Kingdom (UK) have succeeded ahead of the full EU transition from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR) and the UK transition to the United Kingdom Conformity Assessed (UKCA) mark. As of January 2026, we have 22 MDR CE marks and 18 UKCA approvals. Those 22 CE and 18 UKCA marks represent substantially all of our product approvals in the EU and UK. The European Commission has designated the end of 2028 as the final MDR CE mark transition deadline.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Additionally, we provide cryopreservation services for our RestoreFlow allografts primarily in the US, the UK, and Canada. In October 2025, we received approval from the German authority on tissue banking to allow sale of these services in the German market.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On July 4, 2025, President Donald Trump signed the One Big Beautiful Bill Act ("OBBA") into law, which is considered the enactment date under US GAAP. Key corporate tax provisions include the restoration of 100% bonus depreciation for qualifying assets, immediate expensing for domestic research and experimental expenditures, changes to Section 163(j) interest limitations, updates to U.S. tax rules on international sales and operations, amendments to energy credits, and expanded Section 162(m) aggregation requirements.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In 2025, we implemented provisions of the OBBA, fully recognizing the deduction of domestic research and experimental expenditures previously capitalized under Section 174 of the Internal Revenue Code. As a result of this
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
implementation, we adjusted our deferred tax assets and deferred tax liabilities to reflect the change in tax treatment for these expenditures. The impact of these adjustments is reflected in our 2025 tax provision and financial statements. We will continue to monitor future legislative developments and assess their impact on our tax position and financial reporting.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
As part of the Company’s normal course of business, the Company has commitments to purchase approximately $9.1 million of inventory through 2026. These purchases are to be used in the normal course of business and do not represent excess commitments or loss contracts.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of consolidated financial statements requires management to make estimates and judgments that affect
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
the reported amounts of assets and liabilities, net sales, costs and expenses, and related disclosures. On a periodic basis, we evaluate our estimates, using authoritative pronouncements, historical experience and other assumptions as the basis for making estimates. We have described our significant accounting policies in Note 1 to our consolidated financial statements included in this Form 10-K.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
We believe the following critical accounting policies involve a significant level of estimation uncertainty and judgments that are reasonably likely to have a material impact on our consolidated financial statements. We base our judgments and estimates on historical experience, current conditions and other reasonable factors. Actual results could differ from those estimates under different assumptions or conditions.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
To assist us in evaluating our business strategies, we monitor long-term technology trends in the peripheral vascular device market. Additionally, we consider the information obtained from discussions with the medical community in connection with the demand for our products, including potential new product launches. We also use this information to help determine our competitive position in the peripheral vascular device market and our manufacturing capacity requirements.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Separately, in July 2024, we received MDR CE marks allowing for the continued sale of ten devices into the EU. Previously we had obtained four MDR CE marks. In January 2025, we received MDR CE marks to market Burlington-manufactured CardioCel and VascuCel devices in the EU. In total, we expect to receive 23 MDR CE marks by the end of 2025. The European Commission has designated the end of 2028 as the final MDR CE mark deadline.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
In October 2018, we acquired the Cardial business from Becton Dickinson. Cardial manufactured polyester vascular grafts, valve cutters and surgical glue at its St. Etienne, France facility. In June 2022, we closed the St. Etienne factory to streamline manufacturing operations and to reduce expenses. We are transitioning Cardial graft sales to our Burlington-manufactured AlboGraft product for additional cost savings and improved margins.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Restructuring. For the year ended December 31, 2024, there were no restructuring expenses. On June 30, 2022, we ceased operations at our St. Etienne, France factory. The closure resulted in a restructuring charge of $3.1 million for the year ended December 31, 2022. These charges consisted primarily of employment termination costs, impairment of fixed assets and inventory, and third-party costs. For the year ended December 31, 2023, we recorded additional restructuring expenses related to this closure of $0.5 million. The additional expenses consisted primarily of employment termination, settlement, legal, and other third-party costs. As a percentage of sales, restructuring expenses was less than 1% for the year ended December 31, 2023.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
We monitor the mix of profitability by tax jurisdiction and adjust our annual expected rate on a quarterly basis as needed. While it is often difficult to predict the final outcome or timing of the resolution for any particular tax matter, we believe our tax reserves reflect the probable outcome of known contingencies.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to amortize such expenditures over five years for tax purposes. This provision resulted in a cash tax liability for the 2024 tax year of approximately $0.8 million. Our net deferred tax assets increased in 2024 by approximately $0.9 million as a result as well. This provision is also expected to increase our 2025 cash tax liability. The actual impact on 2025 cash tax liability will depend on the amount of research and development expenses paid or incurred in 2025 among other factors. The impact will continue over the five-year amortization period, but will decrease ratably over the period.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Restructuring. For the year ended December 31, 2023, restructuring expenses were $0.5 million. On June 30, 2022, we ceased operations at our St. Etienne, France factory. The closure resulted in a restructuring charge of $3.1 million for the year ended December 31, 2022. These charges consisted primarily of employment termination costs, impairment of fixed assets and inventory, and third-party costs. For the year ended December 31, 2023, we recorded additional restructuring expenses related to this closure of $0.5 million. The additional expenses consisted primarily of employment termination, settlement, legal, and other third-party costs. As a percentage of sales, restructuring expenses was less than 1% for the year ended December 31, 2023, down from 2% in the prior period.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
The Company incurred a cash tax liability for the 2023 tax year of approximately $0.7 million and an increase in our net deferred tax assets for the 2023 tax year by approximately $0.8 million as a result of the Tax Cuts and Jobs Act of 2017.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of our consolidated financial statements and related disclosures require us to make estimates, assumptions and judgements that affect the reported amounts of assets, liabilities, sales, costs and expenses, and related disclosures. We evaluate our estimates on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
While our significant accounting policies are described in more detail in Note 1 to our consolidated financial statements included in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgements and estimates used in the preparation of our consolidated financial statements.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
We account for income taxes under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred taxes are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The provision for income taxes includes taxes currently payable and deferred taxes resulting from the tax effects of temporary differences between the financial statement and tax bases of assets and liabilities. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in the valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carry-back and carry-forward periods, and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedMD&A
Recent approvals include the approval approvals to sell the XenoSure patch for carotid indication in Japan in May 2023, and the Pruitt Irrigation Occlusion Catheter in China in October 2023, the XenoSure patch for cardiac indication in China in December 2024, and 2023; approvals to sell the Artegraft bovine graft in Thailand and Malaysia in August 2024 and in South Africa in October 2024. 2024, and the XenoSure patch for cardiac indications in China in December 2024; and approvals to sell the Artegraft bovine graft in the European Union (EU) in April 2025, Australia in June 2025, and Canada in December 2025, the Pruitt Aortic Occlusion Catheter in the EU in May 2025, and the Pruitt Occlusion Catheter in China in June 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Net cash provided by operating activities was $44.1 $81.3 million for the year ended December 31, 2024, 2025, consisting of $44.0 $57.7 million net income, adjusted for non-cash items of $20.2 $25.3 million (including primarily depreciation and amortization of $9.7 $10.4 million, stock-based compensation of $6.6 $7.8 million, provisions for inventory write-offs and credit losses of $3.9 $3.5 million, provision for deferred income taxes of $2.3 million, amortization of issuance costs on convertible senior notes of $0.9 million, and unrealized mark-to-market loss on equity investments of $0.5 million, offset by foreign currency transaction effect on income of $0.4 million, and fair value adjustments to contingent consideration obligations of $0.1 million, offset by a provision for deferred income taxes of $0.5 $0.2 million), as well as cash used for working capital of $20.1 $1.7 million.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We recorded a tax provision of $17.5 million on pre-tax income of $75.2 million for the year ended December 31, 2025, compared to $12.8 million on pre-tax income of $56.9 million for the twelve months year ended December 31, 2024, compared to $9.4 million on pre-tax income of $39.5 million for the twelve months ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our cash and cash equivalents are liquid short-term marketable securities primarily include corporate debt securities, U.S. government agency securities, money market investments with maturities of 90 days or less at the date of purchase and consist primarily held outside of our operating bank accounts. accounts, and a short-duration bond equity fund.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The net cash used for working capital was driven by increases in inventory and other deferred costs of $10.6 million, $7.2 million and increases in accounts receivable of $6.4 $2.9 million, offset by increases in accounts payable and other liabilities of $4.2 million, decreases in prepaid expenses and other assets of $2.3 $2.4 million, and decreases increases in accounts payable and other liabilities accrued interest of $0.8 $1.8 million.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Gross profit increased $23.9 $27.6 million, or 19%, 18%, to $178.5 million for the year ended December 31, 2025, as compared to $150.9 million for the year ended December 31, 2024, and gross margin increased by 290 basis points to 68.6% 71.5% in the period. period, as compared to 68.6% for the year ended December 31, 2024.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The increase was driven primarily by increased sales of grafts of $5.1 million, which includes the launch of Artegraft, shunts of $2.8 million, catheters of $2.1 million, patches of $3.3 million, grafts of $3.0 million, shunts of $1.9 $1.8 million, and valvulotomes of $1.1 $1.3 million.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Other income (expense) primarily includes interest income and expense, dividend income, realized gains (losses) from the sale of debt and equity investments, unrealized gains (losses) from equity investments, interest expense for the convertible senior notes, foreign currency gains (losses), and other miscellaneous gains (losses).
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We have been preparing for this transition since 2022 and have hired an experienced consulting team to assist in this transition, and, in In the U.S., United States, we transitioned from our legacy ERP system to our newly implemented Microsoft Dynamics D365 system in February 2024.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our cost Cost of sales consists primarily of manufacturing personnel, personnel wages, raw materials and components, depreciation of property and equipment, and other allocated manufacturing overhead, as well as the freight expense we pay to ship products to customers. including an allocation of our quality department expenses.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Net sales increased by $26.4 $29.7 million, or 14%, to $249.6 million for the year ended December 31, 2025, compared to $219.9 million for the year ended December 31, 2024, compared to $193.5 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We believe that our cash, cash and cash equivalents, investments, short-term marketable securities, and the interest we earn on these balances will enable us to fund our operating expenses, capital expenditures requirements, and Convertible Note interest payments for at least twelve months following the filing of our annual report on this Form 10-K and, together with our anticipated future cash, cash equivalents, and short-term marketable securities, to meet our known long-term cash requirements.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesMD&A
Under the agreement, we can could distribute the products for three years with an option to acquire Elutia’s worldwide cardiovascular porcine patch business during the second and third year years of the agreement.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesMD&A
In certain limited cases our products are held on consignment at a hospital or clinic prior to purchase; in those instances we recognize revenue at the time the product is used in surgery rather than at shipment.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LMAT/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.